These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 30777124)
1. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Shrestha R; Nabavi N; Lin YY; Mo F; Anderson S; Volik S; Adomat HH; Lin D; Xue H; Dong X; Shukin R; Bell RH; McConeghy B; Haegert A; Brahmbhatt S; Li E; Oo HZ; Hurtado-Coll A; Fazli L; Zhou J; McConnell Y; McCart A; Lowy A; Morin GB; Chen T; Daugaard M; Sahinalp SC; Hach F; Le Bihan S; Gleave ME; Wang Y; Churg A; Collins CC Genome Med; 2019 Feb; 11(1):8. PubMed ID: 30777124 [TBL] [Abstract][Full Text] [Related]
2. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. Ladanyi M; Sanchez Vega F; Zauderer M Genome Med; 2019 Mar; 11(1):18. PubMed ID: 30914057 [TBL] [Abstract][Full Text] [Related]
3. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas. Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829 [TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of diffuse malignant peritoneal mesothelioma. Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035 [TBL] [Abstract][Full Text] [Related]
5. A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma. Lai J; Zhou Z; Tang XJ; Gao ZB; Zhou J; Chen SQ Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187383 [TBL] [Abstract][Full Text] [Related]
6. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843 [TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769 [TBL] [Abstract][Full Text] [Related]
8. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512 [TBL] [Abstract][Full Text] [Related]
9. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens. Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897 [TBL] [Abstract][Full Text] [Related]
10. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members. Kittaneh M; Berkelhammer C J Transl Med; 2018 Jul; 16(1):194. PubMed ID: 30001711 [TBL] [Abstract][Full Text] [Related]
11. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Baumann F; Flores E; Napolitano A; Kanodia S; Taioli E; Pass H; Yang H; Carbone M Carcinogenesis; 2015 Jan; 36(1):76-81. PubMed ID: 25380601 [TBL] [Abstract][Full Text] [Related]
12. Targeting BAP1: a new paradigm for mesothelioma. Schunselaar LM; Zwart W; Baas P Lung Cancer; 2017 Jul; 109():145-146. PubMed ID: 28342657 [TBL] [Abstract][Full Text] [Related]
13. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer. Ohar JA; Cheung M; Talarchek J; Howard SE; Howard TD; Hesdorffer M; Peng H; Rauscher FJ; Testa JR Cancer Res; 2016 Jan; 76(2):206-15. PubMed ID: 26719535 [TBL] [Abstract][Full Text] [Related]
14. Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis? Pulford E; Huilgol K; Moffat D; Henderson DW; Klebe S Dis Markers; 2017; 2017():1310478. PubMed ID: 29085180 [TBL] [Abstract][Full Text] [Related]
15. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Napolitano A; Pellegrini L; Dey A; Larson D; Tanji M; Flores EG; Kendrick B; Lapid D; Powers A; Kanodia S; Pastorino S; Pass HI; Dixit V; Yang H; Carbone M Oncogene; 2016 Apr; 35(15):1996-2002. PubMed ID: 26119930 [TBL] [Abstract][Full Text] [Related]